CPRX
HEALTHCARECatalyst Pharmaceuticals Inc
$30.52-0.34 (-1.10%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CPRX Today?
No stock-specific AI insight has been generated for CPRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$19.05$32.56
$30.52
Fundamentals
Market Cap$3.7B
P/E Ratio18.2
EPS$1.68
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin0.4%
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding122.3M
CPRX News
20 articles- Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bnHospitalmanagement·May 8, 2026
- Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and WebcastYahoo Finance·May 7, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·May 7, 2026
- UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong OutlookYahoo Finance·May 7, 2026
- ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthYahoo Finance·May 7, 2026
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpYahoo Finance·May 7, 2026
- RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YYahoo Finance·May 7, 2026
- Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key MetricsYahoo Finance·May 7, 2026
- Angelini to buy Catalyst in $4B play for rare neuro drugsBiopharmadive·May 7, 2026
- Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion DealWall Street Journal·May 7, 2026
- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.GlobeNewswire Inc.·May 7, 2026
- Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare DiseaseBenzinga·May 7, 2026
- OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookYahoo Finance·May 6, 2026
- RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectYahoo Finance·May 6, 2026
- EDIT's Q1 Loss Narrower Than Expected, Pipeline in FocusYahoo Finance·May 6, 2026
- JAZZ Stock Jumps as Q1 Earnings & Sales Surpass ExpectationsYahoo Finance·May 6, 2026
- Bioventus (BVS) Surpasses Q1 Earnings and Revenue EstimatesYahoo Finance·May 6, 2026
- Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In FocusYahoo Finance·May 5, 2026
- BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedYahoo Finance·May 5, 2026
- Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in FocusYahoo Finance·May 5, 2026
All 20 articles loaded
Price Data
Open$31.07
Previous Close$30.86
Day High$31.19
Day Low$30.17
52 Week High$32.56
52 Week Low$19.05
52-Week Range
$19.05$32.56
$30.52
Fundamentals
Market Cap$3.7B
P/E Ratio18.2
EPS$1.68
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin0.4%
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding122.3M
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—